If you didn’t tune in for the riveting Senate hearing over the nomination of the new NIH Director Monica Bertagnolli, you might have missed the back-and-forth between Senators Sanders and Cassidy over whether the NIH should exercise march-in rights as to overpriced pharmaceuticals that were developed with NIH funding.